Table 5.
Association of Genotypes with Tumor Characteristics in All Patients
| Variable | Genotype | No. (%) | No. (%) | P (χ2) | OR† (95% CI) | P† |
|---|---|---|---|---|---|---|
| Response to Therapy | PR/SD | PD | ||||
| IGF1R IVS2-70184A>G | .001 | |||||
| AA | 108 (90.8) | 11 (9.2) | 1.0 | |||
| GA/GG | 116 (75.8) | 37 (24.2) | 4.81 (2.02–11.4) | <.001 | ||
| IGF1R IVS15+1950A>G | .001* | |||||
| GG | 51 (98.1) | 1 (1.9) | 1.0 | |||
| GA/AA | 186 (79.8) | 47 (20.2) | 14.3 (1.77–115) | .01 | ||
| IGF2R L252V | .01* | |||||
| CC/CG | 237 (84.0) | 45 (16.0) | 1.0 | |||
| GG | 1 (25.0) | 3 (75.0) | 23.8 (1.98–287) | .01 | ||
| IGF2R L2222L | .001 | |||||
| CC | 198 (86.8) | 30 (13.2) | 1.0 | |||
| TC/TT | 40 (69.0) | 18 (31.0) | 3.58 (1.59–8.06) | .002 | ||
| IRS1 G972R | <.001 | |||||
| GG | 217 (86.1) | 35 (13.9) | 1.0 | |||
| GA/AA | 21 (61.8) | 12 (36.2) | 3.71 (1.43–9.59) | .007 | ||
| Tumor Stage | Localized | Advanced | ||||
| IGF1R IVS2-70184A>G | <.001 | |||||
| AA | 162 (62.1) | 99 (37.9) | 1.0 | |||
| GA | 122 (41.4) | 173 (58.6) | 2.31 (1.57–3.39) | <.001 | ||
| GG | 33 (28.9) | 81 (71.1) | 4.23 (2.48–7.19) | <.001 | ||
| IGF1 Ex4+2776G>A | <.001 | |||||
| GG | 178 (58.2) | 128 (41.8) | 1.0 | |||
| GA | 100 (42.7) | 134 (57.3) | 1.82 (1.24–2.66) | .002 | ||
| AA | 23 (37.1) | 39 (62.9) | 2.62 (1.40–4.89) | .003 | ||
| IRS2 Ex2+750A>G | .004 | |||||
| AA/GG | 141 (41.7) | 197 (58.3) | 1.0 | |||
| GA | 192 (52.5) | 174 (47.5) | 0.66 (0.47–0.92) | .01 | ||
| IRS2 IVS1+5687T>C | <.001 | |||||
| TT | 205 (60.8) | 132 (39.2) | 1.0 | |||
| CT/CC | 121 (35.3) | 222 (64.7) | 2.51 (1.78–3.55) | <.001 | ||
| Tumor Resectability | Resectable | Unresectable | ||||
| IGF1R IVS2-70184A>G | .002 | |||||
| AA | 119 (45.6) | 142 (54.4) | 1.0 | |||
| GA | 112 (38) | 183 (62) | 1.20 (0.82–1.77) | .34 | ||
| GG | 30 (26.3) | 84 (73.7) | 2.16 (1.26–3.70) | .005 | ||
| IGF1 Ex4+2776G>A | .002 | |||||
| GG | 143 (46.7) | 163 (53.3) | 1.0 | |||
| GA/AA | 102 (34.5) | 194 (65.5) | 1.63 (1.13–2.36) | .007 | ||
| IRS2 IVS1+5687T>C | <.001 | |||||
| TT | 164 (48.7) | 173 (51.3) | 1.0 | |||
| CT/CC | 104 (30.3) | 239 (69.7) | 1.83 (1.29–2.60) | .001 | ||
| IGF1R T766T | .002 | |||||
| CC | 257 (40.9) | 371 (59.1) | 1.0 | |||
| CT/TT | 18 (23.1) | 60 (76.9) | 2.48 (1.33–4.63) | .004 | ||
OR, odds ratio; CI, confidence interval; PR, partial response; SD, stable disease; PD, progressive disease; CA19-9, carbohydrate antigen 19-9.
*
P value from Fisher’s exact (2-sided) test.
†
OR was calculated from logistic regression adjusted sex, race, clinical stage, tumor resection, CA 19-9, biochemical index and performance status when appropriate.